Free Trial

Unison Advisors LLC Invests $2.68 Million in Humana Inc. (NYSE:HUM)

Humana logo with Medical background

Unison Advisors LLC bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,100 shares of the insurance provider's stock, valued at approximately $2,681,000.

Other institutional investors have also added to or reduced their stakes in the company. denkapparat Operations GmbH purchased a new position in shares of Humana in the 4th quarter worth approximately $323,000. Allstate Corp purchased a new stake in shares of Humana in the 4th quarter valued at $905,000. Deutsche Bank AG boosted its holdings in shares of Humana by 18.2% in the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock valued at $160,185,000 after acquiring an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Humana in the 1st quarter valued at $1,309,000. Finally, Fred Alger Management LLC acquired a new position in shares of Humana in the 4th quarter valued at $451,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Up 3.9%

Shares of HUM traded up $9.01 during mid-day trading on Friday, reaching $238.22. The stock had a trading volume of 1,569,145 shares, compared to its average volume of 1,505,668. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $406.09. The business's fifty day moving average is $234.56 and its 200 day moving average is $256.27. The firm has a market cap of $28.75 billion, a price-to-earnings ratio of 16.85, a P/E/G ratio of 1.57 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $7.23 earnings per share. On average, sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Wells Fargo & Company set a $348.00 target price on shares of Humana in a research note on Friday, July 18th. Guggenheim started coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price for the company. Mizuho upped their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Bank of America reduced their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Finally, Wall Street Zen upgraded shares of Humana from a "hold" rating to a "buy" rating in a research report on Sunday, July 20th. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, Humana currently has an average rating of "Hold" and a consensus price target of $282.43.

View Our Latest Stock Analysis on HUM

About Humana

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Should You Invest $1,000 in Humana Right Now?

Before you consider Humana, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.

While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines